Geospatial distribution of Hepatitis E seroprevalence in Nepal, 2021
Authors:
Open Access
- 23 December 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 18 (12) , e0012746
Abstract
Background: Hepatitis E virus (HEV) causes acute jaundice and poses an important public health problem in low- and middle-income countries. Limited surveillance capacity and suboptimal access to diagnostics leads to under-reporting of HEV infections in affected countries, including Nepal. Serum antibodies against HEV are indicative of past infection. We analyzed existing samples from a nationally representative serosurvey to describe the geospatial distribution and factors associated with HEV seroprevalence in Nepal, as a proxy for infection. Methodology/Principle findings: A nationally representative cross-sectional serosurvey of 3,922 individuals ≥2 years old from 975 households spread across 65 wards throughout Nepal was conducted between November 2021 and January 2022. Bio-banked samples were tested for anti-HEV IgG. Seroprevalence and its 95% confidence interval were estimated by age, sex, ecological region, municipality type, and other waterborne-disease related risk factors. Bayesian geostatistical models were fitted to observed seroprevalence data and used to generate high-resolution maps of seroprevalence across Nepal. Available samples from 3,707 participants were tested for anti-HEV IgG, and 3,703 were used for final analysis. We found 20.8% (95% CI: 19.5–22.2) of participants had evidence of prior HEV infection. HEV seroprevalence increased with age, and was higher in males (23.5%, 95% CI: 21.5–25.5) than in females (18.6%, 95% CI: 16.9–20.3). Seroprevalence in hilly (28.9%, 95% CI: 26.6–31.2) and mountain (24.6%, 95% CI: 18.8–30.5) regions were significantly higher than in terai (14.2%, 95% CI: 12.7–15.8). While there was no significant difference between urban and rural populations, the predicted seroprevalence was highest in Kathmandu, the capital of Nepal, reaching seroprevalence of 50% in some selected area. No statistically significant differences were found for wealth quintile, water source, and toilet facility. Conclusions: This study provides population-based serologic evidence that HEV is endemic in Nepal, with the greatest risk of infection in Kathmandu.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-039469)
- Global Disease Eradication Fund (2020-2025)
This publication has 26 references indexed in Scilit:
- Annual risk of hepatitis E virus infection and seroreversion: Insights from a serological cohort in Sitakunda, BangladeshEpidemiology and Infection, 2024
- Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2024
- A 10-Year Immunopersistence Study of Hepatitis E Antibodies in Rural BangladeshAmerican Journal of Epidemiology, 2018
- A global map of travel time to cities to assess inequalities in accessibility in 2015Nature, 2018
- Hepatitis E: a neglected virusThe Lancet Gastroenterology & Hepatology, 2016
- First report of hepatitis E virus viremia in healthy blood donors from NepalVirusDisease, 2016
- Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest FranceJournal of Clinical Virology, 2015
- Epidemiology of Hepatitis E in Low- and Middle-Income Countries of Asia and AfricaSeminars in Liver Disease, 2013
- Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trialThe Lancet, 2010
- Molecular investigation of hepatitis E virus infection in patients with acute hepatitis in Kathmandu, NepalJournal of Medical Virology, 2002